Next Article in Journal
A Mechanism Underlying Attenuation of Recombinant Influenza A Viruses Carrying Reporter Genes
Next Article in Special Issue
CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice
Previous Article in Journal
Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus
Previous Article in Special Issue
A Human DPP4-Knockin Mouse’s Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV
Open AccessReview

Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection

1
School of Health Sciences, and State Key Laboratory of Virology, Wuhan University, Wuhan 430071, China
2
Fudan University School of Medicine, Shanghai 200032, China
*
Author to whom correspondence should be addressed.
Viruses 2018, 10(12), 680; https://doi.org/10.3390/v10120680
Received: 19 November 2018 / Revised: 28 November 2018 / Accepted: 29 November 2018 / Published: 30 November 2018
(This article belongs to the Special Issue MERS-CoV)
Since emerging in 2012, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has been a global public health threat with a high fatality rate and worldwide distribution. There are no approved vaccines or therapies for MERS until now. Passive immunotherapy with neutralizing monoclonal antibodies (mAbs) is an effective prophylactic and therapeutic reagent against emerging viruses. In this article, we review current advances in neutralizing mAbs against MERS-CoV. The receptor-binding domain (RBD) in the spike protein of MERS-CoV is a major target, and mouse, camel, or human-derived neutralizing mAbs targeting RBD have been developed. A major problem with neutralizing mAb therapy is mutant escape under selective pressure, which can be solved by combination of neutralizing mAbs targeting different epitopes. Neutralizing mAbs are currently under preclinical evaluation, and they are promising candidate therapeutic agents against MERS-CoV infection. View Full-Text
Keywords: Middle East Respiratory Syndrome Virus; MERS-CoV; neutralizing monoclonal antibodies Middle East Respiratory Syndrome Virus; MERS-CoV; neutralizing monoclonal antibodies
Show Figures

Figure 1

MDPI and ACS Style

Han, H.-J.; Liu, J.-W.; Yu, H.; Yu, X.-J. Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection. Viruses 2018, 10, 680.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop